Eddingpharm, Syndax deal

Eddingpharm received exclusive rights to develop and commercialize Syndax's entinostat in China, Thailand, Taiwan and Malaysia. Syndax is eligible for undisclosed milestones and royalties. Eddingpharm can participate in the first three global Phase III registration trials of entinostat for any indication that would satisfy the China Food and Drug Administration (CFDA) requirements for approval in China. Eddingpharm will be responsible for all development costs in China. The companies will share all data. ...